23:22 , Jul 25, 2019 |  BC Innovations  |  Distillery Therapeutics

RBP3 as a therapy for diabetic retinopathy

DISEASE CATEGORY: Ophthalmic INDICATION: Diabetic retinopathy The retinol binding protein RBP3 could treat or prevent the development of diabetic retinopathy. Levels of RBP3 protein in the retina and vitreous were lower in 23 patients with...
21:23 , Jul 3, 2019 |  BC Extra  |  Clinical News

July 3 Clinical Quick Takes: GSK starts Phase III otilimab RA program; plus Unum, Xofluza and more

Otilimab triggers milestone for MorphoSys MorphoSys AG (Xetra:MOR; NASDAQ:MOR) will receive a milestone payment of €22 million ($27.7 million) after partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) started the Phase III ContRAst program of otilimab to treat...
15:04 , May 7, 2019 |  BC Extra  |  Clinical News

Viela reports detailed Phase II/III data for rare CNS disorder therapy

Viela touted a potential dosing advantage and reiterated its plans to submit mid-year a BLA to FDA for inebilizumab to treat neuromyelitis optica spectrum disorder (NMOSD). The update came during a presentation at AAN on...
20:51 , Mar 26, 2019 |  BC Extra  |  Company News

Japan approvals include Kymriah as Japan's first CAR T therapy

Japanese regulators approved a basket of drugs on Tuesday, including the first CAR T cell therapy in Japan. Novartis AG (NYSE:NVS; SIX:NOVN) said Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Kymriah tisagenlecleucel to...
13:06 , Mar 13, 2019 |  BC Innovations  |  Distillery Therapeutics

IKKβ inhibition for tendinopathy

DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal Patient sample, cell culture and mouse studies suggest inhibiting IKKβ could help treat tendinopathy. In tendon tissues samples from patients with rotator cuff disease, levels of IKKβ protein were higher...
21:16 , Mar 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting GM-CSF in CAR Ts to prevent therapy-induced cytokine release syndrome

DISEASE CATEGORY: Inflammation INDICATION: Cytokine release syndrome (CRS) Cell culture studies suggest inhibiting GM-CSF produced by CAR T cells could help prevent CRS in lymphoma patients receiving CAR T therapies. In a co-culture assay in...
13:02 , Feb 28, 2019 |  BC Extra  |  Preclinical News

Removing genes from CAR Ts to improve efficacy, safety

Two studies have identified genes that could be knocked out from CAR T cells to improve efficacy or safety. While CAR T cells are effective against B cell malignancies, their efficacy in solid tumors has...
03:03 , Feb 15, 2019 |  BC Innovations  |  Tools & Techniques

Heartening predictors in diabetes

New biomarkers of cardiovascular risk could relieve a decade-old bottleneck for diabetes drug development, but validating them will require companies to invest in strategic trial designs, and public and private stakeholders to pool thinking. As...
03:03 , Jan 26, 2019 |  BioCentury  |  Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
19:07 , Jan 4, 2019 |  BC Week In Review  |  Clinical News

Viela planning BLA submission for inebilizumab in rare CNS disorder

Viela Bio Inc. (Gaithersburg, Md.) said it will submit a BLA to FDA this half for inebilizumab (MEDI-551) to treat neuromyelitis optica spectrum disorder (NMOSD) after the compound met the primary endpoint in the Phase...